Custom Search

News

Thursday 01 June 2006

Long-term followup shows dyslipidemic patients benefited from early gemfibrozil treatment

 

Long-term follow up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome.

According to a report from Finland, "The Helsinki Heart Study was a double-blind, placebo-controlled primary prevention trial among 4081 dyslipidemic middle-aged men to test the efficacy of gemfibrozil in the prevention of coronary heart disease (CHD)."

"After the 5-year trial, the participants were notified of their treatment group and invited to continue or start gemfibrozil therapy free of charge through 1995," explained L. Tenkanen and colleagues of the Helsinki Heart Study. "Approximately two thirds of participants in both groups chose gemfibrozil therapy."

"In this 18-year follow-up through 2000, we compared the CHD, cancer, and all-cause mortality among subjects in the original gemfibrozil (OG) group (n 46) with those in the original placebo (OP) group (n 35)," they continued. "To provide an overview of the absolute risks in the 2 treatment groups as well as risk differences between them, we calculated crude mortality rates and presented Kaplan-Meier plots of survival with log-rank tests. We also estimated the relative risks (RRs) using Cox proportional hazards models with and without covariates."

"During the follow-up until 1995, subjects in the OG group had a 32% lower RR of CHD mortality (p=.03) compared with those in the OP group, and when followed up until 2000, the RR was 23% lower (p=.05)," the investigators found. "Overall, there were no differences in all-cause or cancer mortality. However, those in the OG group with both body mass index and triglyceride level in the highest tertiles had a 71% lower RR of CHD mortality (p<.001), a 33% lower RR of all-cause mortality (p=.03), and a 36% lower RR of cancer mortality (p=.22) compared with those in the OP group."

"Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome," the researchers concluded.

Tenkanen and colleagues published their study in the Archives of Internal Medicine (Gemfibrozil in the treatment of dyslipidemia - An 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med, 2006;166(7):743-748).

Read Original Text

Use of this site is subject to the following terms of use